Jason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.
Jason Westin, MD, MS, FACP, director, lymphoma clinical research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, discusses recent developments in novel agents to treat and target aggressive lymphomas.
Patients with aggressive B-cell lymphoma have many new options for treatment, including chimeric antigen receptor (CAR) T cell therapies like axicabtagene ciloleucel (Yes Carta) and lisocabtagene maraleucel (Breyanzi), antibody drug conjugates, and cellular therapies.
According to Westin, experts now are faced with the challenge of figuring out how to best sequence these agents.
0:08 | The current landscape for aggressive B-cell lymphomas is rapidly evolving. We have an excellent problem of lots of new drugs and figuring out how to put them together and how to sequence them. For a long time, we had frontline chemotherapy followed by autologous transplant, and not much else. In the past few years, we've had an avalanche of new approvals, including some cellular therapies, CAR T cells, as well as antibodies, antibody drug conjugates, and small molecules. It's a very exciting time in the management of aggressive B-cell lymphomas.
0:40 | The treatment landscape has evolved significantly over the past decade with the advent of approvals of therapies such as CAR T cell therapies. There are now 3 CAR T cell therapies approved for patients with aggressive B-cell lymphomas. Most recently in the past year, 2 of those have now received an approval for second-line therapy and that's axicabtagene ciloleucel and lisocabtagene maraleucel. Both are now available as second- and third-line treatments and we now have approvals for multiple different agents, including selinexor [Xpovio], tafasitamab [Monjuvi], lenalidomide [Revlimib], bendamustine [Bendeka], rituximab [Rituxan], etc. That's a whole lot of new things that have come along in the past few years. Thankfully, there's a whole bunch more that are coming very soon.